title: When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.
abstract: Lymphoepithelial Kazal-type related inhibitor (LEKTI) is a multidomain proteinase inhibitor whose defective expression causes Netherton syndrome (NS). LEKTI is encoded by SPINK5, which is also a susceptibility gene for atopic disease. In this issue, Fortugno et al. report an elegant and thorough study of the LEKTI proteolytic activation process in which they identify the precise nature of the cleavage sites used and the bioactive fragments generated. They propose a proteolytic activation model in human skin and confirm differential inhibition of kallikrein (KLK) 5, 7, and 14 by the major physiological LEKTI fragments. They show that these bioactive fragments inhibit KLK-mediated proteolysis of desmoglein 1 (DSG1) and suggest a fine-tuned inhibition process controlling target serine proteinase (SP) activity.
authors: INSERM U781, Paris, France.
authors: Laetitia
authors: L
authors: Furio
authors: Alain
authors: A
authors: Hovnanian
mesh_terms: D004817:Epidermis / Q000378:metabolism*; D006706:Homeostasis / Q000502:physiology*; D006801:Humans; D056770:Netherton Syndrome / Q000378:metabolism*; D053491:Proteinase Inhibitory Proteins, Secretory / Q000378:metabolism*; D059748:Proteolysis; D000074163:Serine Peptidase Inhibitor Kazal-Type 5; D012867:Skin / Q000378:metabolism*
chemical_list: D053491:Proteinase Inhibitory Proteins, Secretory; C120650:SPINK5 protein, human; D000074163:Serine Peptidase Inhibitor Kazal-Type 5